Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1992 1
1995 2
1997 1
1999 5
2000 1
2001 3
2002 3
2003 2
2004 4
2005 3
2006 3
2007 4
2008 3
2009 2
2010 5
2011 4
2012 3
2013 11
2014 4
2015 3
2016 4
2017 6
2018 4
2019 2
2020 4
2021 2
2022 4
2023 2
2024 3
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M, Persson JL, Gudas LJ, Rakha E, Robinson BD, Khani F, Martin LM, Moyer JE, Brownlie J, Madhusudan S, Allegrucci C, James VH, Rutland CS, Fray RG, Ntekim A, de Brot S, Mongan NP, Jeyapalan JN. Harris AE, et al. Front Endocrinol (Lausanne). 2022 Oct 3;13:1006101. doi: 10.3389/fendo.2022.1006101. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36263323 Free PMC article. Review.
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D, Tappenden P. Uttley L, et al. Pharmacoeconomics. 2017 Jul;35(7):717-726. doi: 10.1007/s40273-016-0481-1. Pharmacoeconomics. 2017. PMID: 27943135 Free article.
As part of its Single Technology Appraisal Process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of degarelix (Ferring Pharmaceuticals) to submit evidence for the clinical and cost effectiveness of degarelix for the treatment of advanced …
As part of its Single Technology Appraisal Process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of …
Development of 17beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
Ning X, Yang Y, Deng H, Zhang Q, Huang Y, Su Z, Fu Y, Xiang Q, Zhang S. Ning X, et al. Steroids. 2017 May;121:10-16. doi: 10.1016/j.steroids.2017.02.003. Epub 2017 Mar 4. Steroids. 2017. PMID: 28267564 Review.
Additionally, studies have demonstrated that 17beta-HSD3 is over-expressed in hormone-dependent prostate cancer. T, which interacts with the androgen receptor (AR), eventually stimulates the growth of prostate cancer cells. ...
Additionally, studies have demonstrated that 17beta-HSD3 is over-expressed in hormone-dependent prostate cancer. …
Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.
Thomson A, Gunn L, Victor D, Adamson E, Thakrar K. Thomson A, et al. Res Rep Urol. 2024 Oct 9;16:245-252. doi: 10.2147/RRU.S485238. eCollection 2024. Res Rep Urol. 2024. PMID: 39399307 Free PMC article.
BACKGROUND: In the UK, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, is indicated for advanced hormone-sensitive prostate cancer, and as neo-adjuvant and adjuvant treatment in combination with radiotherapy in patients with high-risk localised or locally a …
BACKGROUND: In the UK, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, is indicated for advanced hormone-sensitive pr …
Cannabidiol alters the epigenome of hormone-dependent prostate cancer cells.
Cosgrave J, Magee R, O'reilly E, Hughes C, Jordan A, Silva R, Mccabe A, Dean K, Prencipe M, Gallagher WM, Perry AS. Cosgrave J, et al. Biomed Pharmacother. 2026 Sep 3;203:119891. doi: 10.1016/j.biopha.2026.119891. Online ahead of print. Biomed Pharmacother. 2026. PMID: 42691574 Free article.
The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17beta-Hydroxysteroid Dehydrogenase Type 3.
Cheng Y, Yang Y, Wu Y, Wang W, Xiao L, Zhang Y, Tang J, Huang YD, Zhang S, Xiang Q. Cheng Y, et al. Front Pharmacol. 2020 May 8;11:637. doi: 10.3389/fphar.2020.00637. eCollection 2020. Front Pharmacol. 2020. PMID: 32457626 Free PMC article.
The 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) biosynthesis. ...
The 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) enzyme is a potential therapeutic target for hormone-dependent …
Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.
Liang Y, Mafuvadze B, Aebi JD, Hyder SM. Liang Y, et al. Onco Targets Ther. 2016 May 30;9:3223-32. doi: 10.2147/OTT.S105725. eCollection 2016. Onco Targets Ther. 2016. PMID: 27313468 Free PMC article.
RO treatment reduced androgen receptor protein expression in hormone-dependent prostate cancer cells and increased estrogen receptor beta (ERbeta) protein expression in both hormone-dependent and castration-resistant prostate cancer cell lines. ...
RO treatment reduced androgen receptor protein expression in hormone-dependent prostate cancer cells and increas …
94 results